Results 211 to 220 of about 38,609 (257)

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Hereditary angioedema attack trends among patients maintained on lanadelumab long-term prophylaxis. [PDF]

J Allergy Clin Immunol Glob
O'Connor M, Jacobs J, Panattoni L, Gahlon G, Bariahtaris N, Sing K, Fox D, Schultz BG, Juethner S.   +8 more
europepmc   +1 more source

Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules. [PDF]

Clin Neuropharmacol
LeWitt PA, Klepitskaya O, Olson K, Liang G, Loewen G.   +4 more
europepmc   +1 more source

Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks.

Int Arch Allergy Immunol
Riedl MA, Soteres D, Davis-Lorton MA, Piccolo T, Otule M, Andresen I, Craig T.   +6 more
europepmc   +1 more source

Efficacy and safety of natalizumab extended interval dosing [PDF]

Multiple Sclerosis and Related Disorders, 2018
It is postulated that extending the dosing interval of natalizumab (NTZ) from 4 to 5-8 weeks might decrease the risk of progressive multifocal leukoencephalopathy (PML). The aim of this study was to assess the effect of extended interval dosing (EID) on the therapeutic efficacy of natalizumab.We reviewed 85 patients treated at two MS centers in the ...
Bassem Yamout, Mohammad Ali Sahraian, Hani Tamim   +2 more
exaly   +4 more sources

Personalized extended interval dosing of natalizumab in MS

Neurology, 2020
To determine whether natalizumab efficacy is maintained when switching to personalized extended interval dosing based on individual natalizumab trough concentrations in patients with relapsing-remitting multiple sclerosis (RRMS).This was a prospective multicenter single-arm trial with 1 year follow-up and a 1-year extension phase.
Zoé L.E. van Kempen, Erwin L.J. Hoogervorst, Mike P. Wattjes, Nynke F. Kalkers, Jop P. Mostert, Birgit I. Lissenberg-Witte, Annick de Vries, Anja ten Brinke, Bob W. van Oosten, Frederik Barkhof, Charlotte E. Teunissen, Bernard M.J. Uitdehaag, Theo Rispens, Joep Killestein   +13 more
openaire   +4 more sources

Feasibility of extended dosing intervals of denosumab

Journal of Oncology Pharmacy Practice, 2017
Purpose Denosumab is a crucial supportive care agent for patients with advanced cancers affecting the bone. Despite the importance of treatment, logistical and financial obstacles hinder the ability to maintain long-term adherence.
Jacob K, Kettle, Puja B, Patel
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Extended interval aminoglycoside dosing: from concept to clinic

International Journal of Antimicrobial Agents, 2002
Extended-interval aminoglycoside dosing (EIAD), while a relatively recent concept in mainstream clinical practice, actually has its roots in the mid 1970s. Early trial and error approaches of manipulating the dosage regimen to avoid toxicity and improve efficacy have helped to characterize the pharmacodynamic properties of these drugs.
Dana Maglio, Charles H Nightingale, David P Nicolau   +2 more
exaly   +3 more sources

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Multiple Sclerosis and Related Disorders, 2019
Natalizumab (NTZ) is a highly efficacious therapeutic for multiple sclerosis (MS), but treatment is associated with an increased risk of progressive multifocal leukoencephalopathy (PML). Extended interval dosing (EID) of NTZ has been proposed as an alternative dosing strategy to reduce PML risk. Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of
Susan Goelz
exaly   +3 more sources